Logo
ISO 9001:2000
Menu Arrow
Menu Top
Menu Arrow
Menu Top
Menu Arrow
ISO Certified

Medicare Information Resource

Note: Should you have landed here as a result of a search engine (or other) link, be advised that these files contain material which is copyrighted by the American Medical Association (AMA). You are forbidden to download the files unless you read, agree to and abide by the provisions of the copyright statement. Read the copyright statement now (you will be linked back to here).

Medicare Information Resource Part A
MIR-2006-8AB, August 2006

MLN Matters. . .Information for Medicare Providers
(Issued by the Centers for Medicare & Medicaid Services)

Payment for Blood Clotting Factors Administered to Hemophilia Inpatients

Note: This article was revised on July 10, 2006, to clarify Example 3 and make the example consistent with CR4229.

Provider Types Affected
Providers billing fiscal intermediaries (FIs) for services related to blood clotting factors administered to hemophilia inpatients

Provider Action Needed
This article is based on Change Request (CR) 4229, which clarifies the pricing methodologies used for blood clotting factors. It is especially important to point out that the provider determines the dosage furnished to the patient and, using the definition of the appropriate HCPCS code, translates the dosage into units of service on the claim submitted to Medicare.

Background
The Centers for Medicare & Medicaid Services (CMS) provided CR4229 to clarify billing practices for providers to ensure that units of service for blood clotting factor are reported accurately. Some Medicare providers have been billing units of drugs and biologicals incorrectly on outpatient bills as well as on inpatient claims for hemophilia clotting factors. The erroneous reporting of units of service has resulted in Medicare overpayments.

The provider must determine the actual dosage furnished to the patient and, using the long version of the description of the HCPCS code, translate the dosage into Units of Service. Note: Not all short version descriptions of HCPCS codes define units for the HCPCS code.

The examples below include the Healthcare Common Procedure Coding System (HCPCS) code, and indicate the dosage amount specified in the descriptor of that HCPCS code. Facilities are instructed to use the units’ field as a multiplier to arrive at the dosage amount.

Example 1

HCPCS Code

Drug

Dosage

J9355

Trastuzumab

10 mg

Actual dosage: 140 mg

On the bill, the facility shows HCPCS Code J9355 and 14 in the units of service field (140 mg divided by 10 mg equals 14).

  • When the dosage amount is greater than the amount indicated for the HCPCS code, the facility rounds up to determine units.
  • When the dosage amount is less than the amount indicated for the HCPCS code, use one as the unit of measure.  

Example 2

HCPCS Code

Drug

Dosage

J3100

Tenecteplase

50 mg

Actual Dosage: 40 mg

The provider would bill for one unit, even though less than one full unit was furnished. (40 mg divided by 50 mg equals 0.8)

Example 3

HCPCS Code

Drug

Dosage

J7189

Factor VIIa

1 mcg

Actual Dosage: 13,365 mcg

The provider would bill for J7189 with 13,365 in the units field (13,365 mcg divided by 1 mcg equals 13,365). Note that the process for dealing with one international unit (IU) is the same as the process of dealing with one microgram.

At times, a facility provides less than the amount provided in a single-use vial and there is waste, i.e., some drugs may be available only in packaged amounts that exceed the needs of an individual patient. Once the drug is reconstituted in the hospital’s pharmacy, it may have a limited shelf life.

Since an individual patient may receive less than the fully reconstituted amount, CMS encourages hospitals to schedule patients in such a way that the hospital can use the drug most efficiently. However, if the hospital must discard the remainder of a vial after administering part of it to a Medicare patient, the provider may bill for the amount of drug discarded plus the amount administered, as illustrated in Examples 4 and 5.

Example 4

Drug X is available only in a 100-unit size. A hospital schedules three Medicare patients to receive drug X on the same day within the designated shelf life of the product. An appropriate hospital staff member administers 30 units to each patient. The remaining 10 units are billed to Medicare on the account of the last patient. Therefore:

  • 30 units are billed on behalf of the first patient seen;
  • 30 units are billed on behalf of the second patient seen; and
  • 40 units are billed on behalf of the last patient seen because the hospital had to discard 10 units at that point.

Example 5

Drug X is available only in a 100-unit size. An appropriate hospital staff member must administer 30 units of drug X to a Medicare patient, and it is not practical to schedule another patient who requires the same drug.

For example, the hospital has only one patient who requires drug X, or the hospital sees the patient for the first time and did not know the patient’s condition. The hospital bills for 100 units on behalf of the patient, and Medicare pays for 100 units.

Additional Requirements

CR4229 further instructs your intermediary to:

  • Calculate the payment amount and subtract the charge from those submitted to Pricer so that the clotting factor charges are not included in cost outlier computations;
  • Use the blood-clotting factors HCPCS codes from the Medicare Part B Drug Pricing File, which is made available on a quarterly basis;
  • Use the Average Sales Price (ASP) plus six percent to make payment to facilities that are not paid on cost or Prospective Payment System (PPS);
  • Pay for hemophilia clotting factors during a covered part A stay in a PPS hospital at ASP plus six percent in addition to the Diagnosis Related Group (DRG) payment;
  • Pay the Ambulatory Patient Classification (APC) rate to Outpatient Prospective Payment System (OPPS) hospitals for hemophilia clotting factors administered in inpatient Part B and outpatient settings;
  • Pay for hemophilia clotting factors to beneficiaries based on cost for Part B skilled nursing facility (SNF) services, including inpatient Part B, and all such factors administered by critical access hospitals (CAHs);
  • Pay for hemophilia clotting factors based on cost for non-PPS swing bed services; and
  • Not pay a separate add-on under SNF PPS for SNF or swing bed services.

Note: Providers should no longer divide the number of units by 100 when billing for clotting factors.

Implementation
The implementation date for the instruction is July 14, 2006.*

Additional Information
For complete details, please see the official instruction issued to your intermediary regarding this change. That instruction may be viewed at http://www.cms.hhs.gov/Transmittals/downloads/R903CP.pdf External PDF on the CMS Web site.

If you have any questions, please contact your intermediary at their toll-free number, which may be found at http://www.cms.hhs.gov/MLNProducts/downloads/CallCenterTollNumDirectory.pdf External PDF on the CMS Web site.

Disclaimer
This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents.

MLN Matters Number: MM4229 Revised
Pub. 100-4, Transmittal# R903CP, CR# 4229
Related CR Release Date: April 14, 2006
Effective Date: July 14, 2006
Implementation Date: July 14, 2006

Additional Information Provided by Empire Medicare Services

 *The following new fee rates are effective July 14, 2006.

HCPCS

Description

07/14/2006

Oct 2005

J7188

Injection, von Willebrand Factor Complex, Human, IU

0.878

N/A

J7189

Factor VIIA (Antihemophilic Factor, Recombinant), per 1 microgram

1.076

N/A

J7190

Factor VIII (Antihemophilic Factor, Human) per I.U.

0.677

$64.50

J7191

Factor VIII (Antihemophilic Factor (Porcine)), per I.U.

 

$186.00

J7192

Factor VIII (Antihemophilic Factor, Recombinant) per I.U.

1.062

$105.20

J7193

Factor IX (Antihemophilic Factor, Purified, Non-Recombinant) per I.U.

0.889

$86.90

J7194

Factor IX, Complex, per I.U.

0.727

$65.90

J7195

Factor IX (Antihemophilic Factor, Recombinant) per I.U.

0.987

$98.10

J7198

Anti-Inhibitor, per I.U.

1.348

$129.50


Note: Providers should no longer divide the number of units by 100 when billing for clotting factors.

 

 

   
 
Spacer Image
 Translate this page >> 
 
 
 
 
 
 
 
 
 
 
Copyright